Gulf Shores wants your thoughts on possible music festival extension
Gulf Shores man to compete in 50th season of CBS's 'Survivor'
Hangout Music Festival has been held in Gulf Shores for 15 years, with the last festival being taken over by Morgan Wallen for the 15th year celebration, renaming HMF the 'Sand In My Boots' festival.
City officials have opened two online surveys — one for residents and one for business owners — to find out whether they want the festival to continue. A community meeting has also been scheduled for June 5.
Both surveys are available until June 4.
'Before we make any decision about the future of the Hangout/Sand In My Boots Music Festival, it's essential that we hear from the people who live and work here,' Gulf Shores Mayor Robert Craft said.
'We want to fully understand how the event affects our residents and businesses, both positively and negatively,' Craft continued. 'Your feedback is crucial to ensuring that any action we take reflects the best interests of our community.'
Biloxi man sets Mississippi saltwater fishing record
The city council will decide whether to extend the proposed contract.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Kern County Fair to host admission, ride wristband flash sale on Friday
BAKERSFIELD, Calif. (KGET) — The Kern County Fair is set to host a flash sale online for fair admission and the unlimited ride wristband. Fair organizers said this your only chance to grab the lowest price. During the 12-hour online only flash sale, fair admission will be $9 and $33 for the unlimited ride wristband. Regular price for fair admission is $15 and regular price for the wristband is $45. The flash sale is scheduled from 10 a.m. to 10 p.m. on Aug. 8, only on the Kern County Fair's website. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
Business Upturn
2 hours ago
- Business Upturn
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB
– Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis – KUALA LUMPUR, Malaysia, Aug. 04, 2025 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; 'Cyclacel' or the 'Company'), a biopharmaceutical company developing innovative cancer medicines, highlighted a preclinical study from independent investigators titled, ' Evaluation of antitumor effects of plogosertib, PLK1 inhibitor in biliary tract cancer with BUBR1 as a potential biomarker ' in the journal, Cancer Research, previously reported in a poster at the American Association of Cancer Research 2025 annual meeting.1 The investigators found that several BTC cancer cell lines were sensitive to plogosertib both as monotherapy and in combinations. Consistently with its antimitotic mechanism of action, plogosertib promoted mitotic checkpoint complex (MCC) formation in prometaphase, which induced mitotic arrest resulting in apoptosis of BTC cells. The authors have also found that BUBR1, a critical mitotic checkpoint protein, may be useful as a biomarker to assess plogosertib's effectiveness. BTC cells with high BUBR1 expression were found to be more sensitive to plogosertib compared to those with low expression. The study concluded that BTC cells with high BUBR1 expression are sensitive to the PLK1 inhibitor plogosertib that demonstrate synergistic effects when combined with an ATR inhibitor, which suggest that targeting PLK1 could be an effective strategy for BTC treatment, especially with BUBR1 expression as a potential biomarker to inform optimal combination therapies. About Biliary Tract Cancer (BTC) BTC, also called cholangiocarcinoma, is a rare but aggressive cancer occurring in the biliary tract, a network of small tubes, or ducts, connecting the liver, gallbladder and small intestine. According to estimates from the National Cancer Institute's SEER database annual US incidence of BTC is 4.4 per 100,000. Prognosis for BTC patients is poor with 5-year overall survival of approximately 10–40% even after surgical tumor resection. BTC treatment strategies include chemotherapy, surgery, radiation and targeted medicines depending on location and stage. As these approaches are not curative, there is an urgent, unmet medical need to treat patients with relapsed, refractory and/or unresectable BTC. About Polo-like Kinase and Plogosertib Polo-like kinase 1 (PLK1) is a serine/threonine kinase that plays a central role in cell division or mitosis. PLK1 is an important regulator of the DNA damage cell cycle checkpoint, mitotic entry and exit, spindle formation and cytokinesis, or cell separation into daughter cells. In general, cancer cells, and in particular KRAS mutated and p53(-) cells, are very sensitive to PLK1 depletion. In contrast normal cells with intact cell cycle checkpoints are less sensitive. Pharmacological inhibition of PLK1 in cancer cells blocks proliferation by prolonged mitotic arrest and induces onset of apoptotic death of such cells. Plogosertib (formerly CYC140) is a novel, small molecule, selective and potent PLK1 inhibitor. It has demonstrated impressive efficacy in human tumor xenografts at nontoxic doses. Cyclacel's translational biology program supports the development of plogosertib in solid tumors and leukemias. Preclinical data from independent groups have shown that certain ARID1A- and/or SMARCA-mutated cancers, and cancers associated with DNAJ-PKAc fusions, may benefit from treatment with plogosertib. Additionally, recent data suggest that PLK1 inhibition may be effective in KRAS-mutated metastatic colorectal cancer. PLK1 overexpression correlates with poor patient prognosis in several tumors, including biliary tract, esophageal, fibrolamellar liver, gastric, leukemia, lung, ovarian, and squamous cell cancers, as well as MYC-amplified cancers. Initial dose escalation data from a Phase 1 clinical study of oral plogosertib suggest that the compound is well tolerated with no dose limiting toxicity observed in five dosing schedules. Clinical benefit was observed in patients with adenoid cystic, biliary tract, ovarian, and squamous cell sinus cancers. About Cyclacel Pharmaceuticals, Inc. Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle and mitosis biology. The anti-mitotic program is evaluating plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit Forward-looking Statements This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended and the Safe Harbor provisions of the US Private Securities Litigation Reform Act of 1995, and encompasses all statements, other than statements of historical fact contained in this press release. These forward-looking statements can be identified by terminology such as 'may,' 'could,' 'will,' 'expects,' 'anticipates,' 'aims,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates,' 'targets,' 'likely to', 'understands' and similar statements. These forward-looking statements are based on management's current expectations. However, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. These statements are neither promises nor guarantees but involve known and unknown risks, uncertainties and other important factors and circumstances that may cause Cyclacel's actual results, performance or achievements to be materially different from its expectations expressed or implied by the forward-looking statements, including conditions in the U.S. capital markets, negative global economic conditions, potential negative developments resulting from epidemics or natural disasters, other negative developments in Cyclacel's business or unfavorable legislative or regulatory developments. We caution you therefore against relying on these forward-looking statements, and we qualify all of our forward-looking statements by these cautionary statements. For a discussion of additional factors that may affect the outcome of such forward-looking statements, see our 2024 annual report on Form 10-K, and in particular the 'Risk Factors' section, as well as the other documents filed with or furnished to the SEC by Cyclacel from time to time. Copies of these filings are available online from the SEC at or on the SEC Filings section of our Investor Relations website at These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. These forward-looking statements should not be relied upon as representing Cyclacel's views as of any date subsequent to the date of this press release. All forward-looking statements in this press release are based on information currently available to Cyclacel, and Cyclacel and its authorized representatives assume no obligation to update these forward-looking statements in light of new information or future events. Accordingly, undue reliance should not be placed upon the forward-looking statements. Contact Cyclacel Pharmaceuticals, Inc. Email: [email protected] © Copyright 2025 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc. SOURCE: Cyclacel Pharmaceuticals, Inc. 1 Yoojin Jeong, Yoojin Jeong, et al, Abstract 5406: Evaluation of antitumor effects of plogosertib, PLK1 inhibitor in biliary tract cancer with BUBR1 as a potential biomarker, Cancer Res (2025) 85 (8 Supplement 1): 5406. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
3 hours ago
- Yahoo
Morgan Fairchild, Barbara Eden and More of Loni Anderson's Friends and Costars Remember the Actress as an 'Absolutely Wonderful Woman'
The 'WKRP in Cincinnati' star is being honored by those who knew her on and off setNEED TO KNOW Loni Anderson was best known for her role as Jennifer Marlowe on the CBS sitcom WKRP in Cincinnati The beloved series aired for four seasons, from 1978 to 1982, during which Anderson received three Golden Globe nominations and two Emmy nods Friends and costars are remembering Anderson for her bright and loving spiritFriends and fans are remembering Loni Anderson. The actress, best known for her role as Jennifer Marlowe on the CBS sitcom WKRP in Cincinnati, died just days before celebrating her 80th birthday, which would have been on Tuesday, Aug. 5. Longtime publicist Cheryl J. Kagan announced the news in a statement to the Associated Press on Sunday, sharing that the actress died "following a prolonged illness." As news of the beloved actress' death spread, those who worked with her and knew her off-screen began sharing their cherished memories. Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Tim Reid Tim Reid worked with Anderson on WKRP in Cincinnati, playing Venus Flytrap, a Vietnam veteran turned funky DJ at the station. In his tribute shared on Instagram, Reid wrote, "One of the dearest friends I've had in my life's journey. Such a wonderful woman🙌🏾❤️❤️❤️❤️❤️❤️❤️ We had some fun! 😞I'll miss her and pray that her transition be peaceful and glorious." In an additional comment, Reid revealed Anderson was responsible for his earring, writing, "She didn't tell me it would hurt like hell and damn near got me fired. But I still wear it to this very day. She was a most talented, beautiful and defiant woman⭐️." Morgan Fairchild Morgan Fairchild, who had a few different opportunities to team up with the late actress over the years, remembered her as "the sweetest, most gracious lady." "I am heartbroken to hear of the passing of the wonderful Loni Anderson! We did Bob Hope specials together & a Christmas movie 2 years ago," she posted on X. "I'm just devastated to hear this. Love & condolences to Bob (who was on set every day w her) & her kids and grandkids, who she adored. #RIPLoniAnderson💔💔💔💔💔💔💔." Later, Fairchild shared a photo of Anderson walking off set with her husband, musician Bob Flick. "#Lovely Loni and her beloved husband, Bob, leaving our set. I took this, thinking it was a sweet pic, but now seems especially poignant 💔," she posted on X. Barbara Eden Barbara Eden remembered her friend in a lengthy tribute shared on X, writing, "The news just came through that my dear friend Loni Anderson has passed. Like many, I am absolutely stunned and heartbroken. Our friendship has spanned many years, and news like this is never easy to hear or accept." Eden went on to remember her friend and fellow actress as "a real talent, with razor smart wit and a glowing sense of humor… but, even more than that, she had an impeccable work ethic." "Even beyond that, Loni was a darling lady and a genuinely good person … I am truly at a loss for words. My condolences to her family, her husband Bob, and her children, Deidra and Quinton. Loni, you were one in a trillion, my friend, and even a trillion more." Valerie Perrine Sharing a photo of herself with Anderson and late actor Howard Hesseman — best known for portraying Dr. Johnny Fever on WKRP in Cincinnati — actress Valerie Perrine posted on X, "RIP Loni Anderson! She was one of the nicest actresses in the business." "She was a beautiful, legendary icon! They'll never be another Loni. I miss her. Here's Loni ,Howard and me💔," she continued. Tori Spelling Tori Spelling got the opportunity to work with Anderson when the late actress played Spelling's mom on So Notorious, a parody series based on Beverly Hills, 90210 star's life. In a heartfelt Instagram tribute, she praised Anderson for the "special imprint on my heart, soul, and very being," adding that their bond, "transcends the short time we spent playing mom and daughter on tv." Spelling also credited Anderson for guiding her as the actress "was leaving the metaphysical nest, embarking into adulthood." "She represented kindness, humbleness, and pure grace. She taught me so much. We laughed, we cried, she was as real as they got, while simultaneously knowing her worth. When you think of a star ⭐️, Loni was truly that in every sense," Spelling wrote. "When they say 'don't meet your heroes,' they weren't talking about Loni Anderson. She was everything and more to everyone." The tribute got the attention of Anderson's granddaughter, who thanked Spelling in the comments. "I'm one of Loni's granddaughters and this meant so much to us. Thank you for your kind words, she sang Turn Around to us as well🩷🩷," Megan Hoffman wrote. Cheri Currie Cheri Currie, lead singer of the Runaways, shared a personal photo with Anderson and a large group on X, explaining that her sister, actress Sondra Currie, had been close friends with the late actress for many years. "God Bless and RIP our long time family friend, Loni Anderson. She will be dearly missed. 🙏😔🙏💐❤️💐," she posted. Robert Davi Robert Davi remembered Anderson, his costar in the 1991 TV movie White Hot: The Mysterious Murder of Thelma Todd, in a tribute posted to X. "Sorry to hear of the passing of Loni Anderson! She was a classy, lovely woman - we had a blast filming this true story about Thelma Todd, an actress who had a love affair with Lucky Luciano - RIP Loni," Davi wrote. Jeff Locker Writer and actor Jeff Locker recalled his chance opportunity to get to know Anderson and what it meant to him as someone who grew up watching her on WKRP in Cincinnati. "Rest in Peace, Loni Anderson 💔I can't begin to share how giddy I was when this pic happened. I was hosting a big awards show. There was a big technical malfunction and I had to stall. The magnificent icon Loni Anderson - who I used to watch religiously on WKRP - was in the front row, and I nervously asked her if she could come up on the stage and say hi to everyone, and also so we could show her some love," he recalled. Locker added, "She was so sweet and gracious and just all smiles. And she said, "Let's take a selfie!" Just a legend with a kind, kind heart ❤️." Robert Hays Although the two never acted together, Robert Hays got to know Anderson as they crossed paths in Hollywood and became close over the years. "Today, my dear friend Loni Anderson passed away. She was an absolutely wonderful woman and friend, a wife, mother and grandmother. Love and condolences to Bob, Deidra, Quintin, and all the grandkids. Loni is singing with the angels now. God bless her," he wrote in a tribute shared on X. Read the original article on People Solve the daily Crossword
